<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04248621</url>
  </required_header>
  <id_info>
    <org_study_id>EMC 2019-12-003-001</org_study_id>
    <nct_id>NCT04248621</nct_id>
  </id_info>
  <brief_title>Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients</brief_title>
  <official_title>The Impact of Continuous Versus Intermittent Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients: A Multicenter, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wonju Severance Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eulji University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wonju Severance Christian Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Androgen deprivation therapy (ADT) is a mainstay of prostate cancer treatment to improve
      overall survival for intermediate- and high-risk localized disease as well as metastatic
      disease. While ADT improves survival, it can cause significant morbidity and a decrement in
      quality of life. In particular, ADT is associated with decrease in bone mineral density (BMD)
      and increased risk of fracture.

      Although current guidelines recommend continuous androgen deprivation therapy (CAD) as
      standard therapy for high-risk disease, there has been increasing recognition of adverse
      effects from CAD. Since 1986, intermittent androgen deprivation therapy (IAD) as alternative
      therapeutic strategy for prostate cancer has been proposed to delay development of castration
      resistance and to reduce the side effects of ADT.

      While both CAD and IAD are commonly used in real clinical practice, no prior study examined
      BMD change after CAD or IAD, and assessed whether bone loss would recover during
      off-treatment of IAD. The investigators therefore determine the rate of change in BMD induced
      by ADT (CAD versus IAD) in men with prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To determine the rate of bone mass loss induced by two therapeutic strategies of
      ADT (CAD versus IAD) in men with prostate cancer.

      Design, setting, and participants: the investigators will perform randomized, open label
      clinical trial. Men aged over 50 yrs old with prostate cancer (localized, locally advanced,
      metastatic prostate cancer) who are treated with primary ADT for newly diagnosed prostate
      cancer or salvage ADT at biochemical recurrence following radical prostatectomy will be
      included.

      Participants will be randomly assigned to one of the following treatment arms:

      Arm 1 (CAD): ADT without any discontinuation during study period (12 months).

      Arm 2 (IAD): ADT for the first 6 months of study period, if the prostate-specific antigen
      (PSA) reaches its nadir (&lt; 4 ng/dL) and serum testosterone reaches castration level (&lt; 50
      ng/dL).

      Outcomes:

      Primary outcome: change of L-spine total BMD. Secondary outcomes: change of femur neck BMD,
      incidence rate of osteoporosis, risk of 10 year major osteoporotic fracture, quality of life
      based on Expanded Prostate Cancer Index (EPIC) questionnaire.

      Timing of outcome measurement: at baseline and up to 12 months after randomization.

      Statistical analyses: student's t test for continuous outcomes and Fisher's exact or
      chi-square test for dichotomous outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of L-spine total BMD</measure>
    <time_frame>At baseline and 12 months</time_frame>
    <description>Measured by bone densitometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of femur neck BMD</measure>
    <time_frame>At baseline and 12 months</time_frame>
    <description>Measured by bone densitometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteoporosis</measure>
    <time_frame>At 12 months</time_frame>
    <description>Defined as newly diagnosed osteoporosis based on T-score (≤ -2.5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of 10 year major osteoporotic fracture</measure>
    <time_frame>At 12 months</time_frame>
    <description>Estimated by Fracture Risk Assessment Tool (FRAX®, available at www.sheffield.ac.uk/FRAX)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life after treatment</measure>
    <time_frame>At baseline and 12 months</time_frame>
    <description>Measured by EPIC questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Intermittent Androgen Deprivation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADT including luteinizing hormone-releasing hormone (LHRH) agonist and antagonist, antiandrogen, or maximum androgen blockade (MAB) should be withdrawn after 6 months of ADT, if the prostate-specific antigen (PSA) reaches its nadir (&lt; 4 ng/dL) and serum testosterone reaches castration level (&lt; 50 ng/dL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous Androgen Deprivation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ADT including LHRH agonist and antagonist, antiandrogen, or MAB without any discontinuation during study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprorelin</intervention_name>
    <description>LHRH agonist</description>
    <arm_group_label>Continuous Androgen Deprivation</arm_group_label>
    <arm_group_label>Intermittent Androgen Deprivation</arm_group_label>
    <other_name>Leuprorelin acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>LHRH agonist</description>
    <arm_group_label>Continuous Androgen Deprivation</arm_group_label>
    <arm_group_label>Intermittent Androgen Deprivation</arm_group_label>
    <other_name>Goserelin acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin</intervention_name>
    <description>LHRH agonist</description>
    <arm_group_label>Continuous Androgen Deprivation</arm_group_label>
    <arm_group_label>Intermittent Androgen Deprivation</arm_group_label>
    <other_name>Triptorelin acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>LHRH antagonist</description>
    <arm_group_label>Continuous Androgen Deprivation</arm_group_label>
    <arm_group_label>Intermittent Androgen Deprivation</arm_group_label>
    <other_name>Degarelix acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>Antiandrogen</description>
    <arm_group_label>Continuous Androgen Deprivation</arm_group_label>
    <arm_group_label>Intermittent Androgen Deprivation</arm_group_label>
    <other_name>Casodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flutamide</intervention_name>
    <description>Antiandrogen</description>
    <arm_group_label>Continuous Androgen Deprivation</arm_group_label>
    <arm_group_label>Intermittent Androgen Deprivation</arm_group_label>
    <other_name>Niftolide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maximum androgen blockade</intervention_name>
    <description>Combination therapy with LHRH agonist and antiandrogen</description>
    <arm_group_label>Continuous Androgen Deprivation</arm_group_label>
    <arm_group_label>Intermittent Androgen Deprivation</arm_group_label>
    <other_name>LHRN agonist and antiandrogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Men aged over 50 yrs old with histologically diagnosed prostate cancer (localized, locally
        advanced, metastatic prostate cancer) who are treated with primary ADT for newly diagnosed
        prostate cancer or salvage ADT at biochemical recurrence following radical prostatectomy. .

        Exclusion Criteria:

          1. men with double primary malignancies,

          2. men who have been treated with ADT or other drug therapy such as denosumab,
             bisphosphonate or steroid,

          3. men with osteoporosis at baseline (T-score ≤ -2.5),

          4. men with a known bone disease,

          5. men with poor performance status (i.e. Eastern Cooperative Oncology Group performance
             status 4),

          6. men with life expectancy &lt; 12 months,

          7. men with increased serum PSA levels (≥ 4 ng/dL) or testosterone levels (≥ 50 ng/dL)
             even after 6 month ADT,

          8. men who are not able to understand trial information or informed consent,
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinsung Park, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, Eulji University, College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinsung Park, MD. PhD.</last_name>
    <phone>+82426113533</phone>
    <email>jspark.uro@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Urology, Chungbuk National University, College of Medicine</name>
      <address>
        <city>Cheongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok Joong Yun, MD. PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Kyungpook National University, School of Medicine</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae-Hwan Kim, MD. PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Yeungnam University, College of Medicine</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phil Hyun Song, MD. PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Eulji University, College of Medicine</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinsung Park, MD. PhD.</last_name>
    </contact>
    <contact_backup>
      <last_name>Dae Seon Yoo, MD. PhD.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Konyang University, College of Medicine,</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung Joon Kim, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Chonnam National University, School of Medicine</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eu Chang Hwang, MD. PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Wonkwang University, School of Medicine</name>
      <address>
        <city>Iksan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Chol Park, MD. PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology,Jeonbuk National University Medical School</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Beom Jeong, MD. PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Pusan National University, School of Medicine</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Woo Park, MD. PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Yonsei University Wonju College of Medicine</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Hung Jung, MD. PhD.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Androgen Antagonists</keyword>
  <keyword>Bone Density</keyword>
  <keyword>Prostatic Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Flutamide</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Androgen Antagonists</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

